Domov › Sladkorna bolezen tipa 2 › Oklahoma
Klinične študije za Sladkorna bolezen tipa 2 v Oklahoma
13 študij za Sladkorna bolezen tipa 2 išče udeležence na lokacijah v Oklahoma.
Mesta v Oklahoma
Uradno besedilo študije (angleško)
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- Tekton Research Oklahoma City, Oklahoma City
- South Oklahoma Heart Research Group, Oklahoma City
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07064473A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
- Tekton Research Oklahoma City, Oklahoma City
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07754461A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
- Hightower Clinical, Oklahoma City
- Medical Research International, LLC, Oklahoma City
- Ascension St. John - Jane Phillips Medical Center, Tulsa
Vključevanje udeležencevVabljeni zdravi prostovoljci
Starost 55 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT06112418A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Oklahoma City
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT07743450A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
- Unity Clinical Research, Oklahoma City
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 15. sep. 2026 · NCT07340320A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Lynn Institute of Norman, Norman
- Lynn Health Science Institute, Oklahoma City
- Essential Medical Research, Tulsa
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Alliance for Multispecialty Research, LLC, Norman
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT06897475A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
- Research Site, Oklahoma City
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT07662213AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
- Lynn Institute of Norman, Norman
Vključevanje udeležencevFaza 3
Starost 45 in več · Vsi spoli · Posodobljeno 1. sep. 2026 · NCT07797335A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
- Research Site, Norman
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 31. avg. 2026 · NCT07662109A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
- University of Oklahoma Health Sciences Center, Oklahoma City
Vključevanje udeležencevFaza 3
Starost 10–17 · Vsi spoli · Posodobljeno 7. avg. 2026 · NCT06739122DISCOVERY of Risk Factors for Type 2 Diabetes in Youth
- The University of Oklahoma Health Sciences Center, Oklahoma City
Vključevanje udeležencevOpazovalna študija
Starost 8–15 · Vsi spoli · Posodobljeno 7. maj 2026 · NCT06525259Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
- Lynn Health Science Institute - Oklahoma City, Oklahoma City
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 18. mar. 2026 · NCT07282743Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.